EBAG9
Receptor-binding cancer antigen expressed on SiSo cells
Protein Summary
May participate in suppression of cell proliferation and induces apoptotic cell death through activation of interleukin-1-beta converting enzyme (ICE)-like proteases. This gene was identified as an estrogen-responsive gene. Regulation of transcription by estrogen is mediated by estrogen receptor, which binds to the estrogen-responsive element found in the 5'-flanking region of this gene. The encoded protein is a tumor-associated antigen that is expressed at high frequency in a variety of cancers. Alternate splicing results in multiple transcript variants. A pseudogene of this gene has been defined on chromosome 10. [provided by RefSeq, Jul 2013]
- ENST00000337573
- ENSP00000337675
- ENSG00000147654
- ENST00000395785
- ENSP00000379131
- ENST00000531677
- ENSP00000432082
- ENST00000614147
- ENSP00000477734
- ENST00000620557
- ENSP00000477645
- RCAS1
- EB9
- PDAF
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
kinase perturbation | 0.84 | ||
disease perturbation | 0.79 | ||
cellular component | 0.76 | ||
histone modification site profile | 0.73 | ||
transcription factor binding site profile | 0.69 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 204.49 (req: < 5)
Gene RIFs: 69 (req: <= 3)
Antibodies: 359 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 204.49 (req: >= 5)
Gene RIFs: 69 (req: > 3)
Antibodies: 359 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 2
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0